A 32-year-old woman from Mumbai with PCOS (confirmed by Rotterdam criteria) and infertility for 2 years presents for ovulation induction. She has a BMI of 31 kg/m², irregular cycles, and elevated androgen levels. Previous trial of clomiphene citrate 100 mg daily for 5 days resulted in no follicular development on day 12 ultrasound. FSH is 6 mIU/mL and LH is 12 mIU/mL (LH:FSH ratio 2:1). What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Clomiphene-Resistant PCOS This patient has **clomiphene resistance** — failure to achieve follicular development despite adequate dosing (100 mg daily). PCOS is confirmed (irregular cycles, elevated androgens, elevated LH:FSH ratio). BMI >30 indicates obesity, a modifiable risk factor. ## Management of Clomiphene-Resistant PCOS **Key Point:** Letrozole is now preferred over increased clomiphene doses or immediate gonadotropins in clomiphene-resistant PCOS because it has superior ovulation and pregnancy rates with fewer side effects. ### Why Letrozole? 1. **Mechanism**: Aromatase inhibitor that reduces estrogen-mediated negative feedback on GnRH, increasing FSH preferentially (without increasing LH as much as clomiphene does) 2. **Advantage in PCOS**: - Does not deplete estrogen receptors (unlike clomiphene) - Lowers circulating estrogen, reducing LH suppression - Better ovulation rates in clomiphene-resistant PCOS (60–70% vs. 20–30% with higher clomiphene doses) - Lower multiple pregnancy rate (1–2% vs. 5–10% with clomiphene) - Thinner endometrium risk is lower 3. **Dosing**: 2.5 mg daily for 5 days from day 3 of cycle 4. **Adjunct metformin**: Improves insulin sensitivity, reduces androgens, and enhances ovulation rates in obese PCOS patients **High-Yield:** Letrozole is now considered equivalent to or superior to clomiphene in PCOS and is the preferred agent for clomiphene-resistant cases per ASRM 2021 guidelines. ## Comparison of Options | Option | Rationale | Why Not Here | |--------|-----------|---------------| | Increase CC to 150 mg | Dose escalation strategy | Already failed at 100 mg; further escalation unlikely to work and increases side effects | | **Letrozole ± metformin** | **Second-line for clomiphene resistance; superior in PCOS** | **CORRECT — evidence-based next step** | | Gonadotropins | Third-line; for letrozole resistance | Premature; requires monitoring, more expensive, higher OHSS risk | | Ovarian drilling | Reserved for gonadotropin resistance or patient preference | Not indicated as second-line; invasive; laparoscopy carries surgical risk | **Clinical Pearl:** Before escalating to gonadotropins, always trial letrozole in clomiphene-resistant PCOS. Letrozole has become the preferred second-line agent because it addresses the underlying pathophysiology (excessive LH suppression by estrogen in PCOS) better than increasing clomiphene dose. ## Lifestyle Optimization **Warning:** Do not overlook weight loss in obese PCOS patients. A 5–10% weight reduction can restore ovulation in 30–40% of women, potentially avoiding pharmacotherapy altogether. Metformin + lifestyle modification should be concurrent with letrozole. ## Monitoring During Letrozole Therapy - Pelvic ultrasound on day 12–13 to assess follicular development - Trigger ovulation with hCG (5,000–10,000 IU) when dominant follicle reaches 18–20 mm - Serum progesterone on day 21 to confirm ovulation - If no response to letrozole 2.5 mg, escalate to 5 mg daily (max 7.5 mg daily) **Mnemonic:** **PCOS Ovulation Induction Ladder** — **CC → Letrozole → Gonadotropins → Ovarian Drilling** - CC (clomiphene citrate) first-line in lean PCOS - Letrozole first-line in obese PCOS or CC-resistant - Gonadotropins for letrozole resistance - Ovarian drilling for gonadotropin resistance or patient preference